Gilead Sciences is a large biopharmaceutical company that develops medicines for conditions with unmet needs. Its filings show it lobbies on health and Medicare/Medicaid issues, including reform and transparency of the 340B drug pricing program, federal funding for HIV prevention, and laws about how drugs are negotiated and priced under the federal Drug Price Negotiation Program. It disclosed hiring The McManus Group and reported $240,000 in lobbying since 2026 filings began.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JOHN MCMANUS
The latest disclosures for this client.
THE MCMANUS GROUP
Q1THE MCMANUS GROUP
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE MCMANUS GROUP
THE MCMANUS GROUP
Q3THE MCMANUS GROUP
Q2THE MCMANUS GROUP
Q1